Today’s Research Reports on Trending Tickers: Nektar Therapeutics and Corcept Therapeutics

NEW YORK, NY / ACCESSWIRE / May 21, 2018 / U.S. markets finished lower on Friday, and posted weekly drop as uncertainty on trade negotiations linger on the market. The Dow Jones Industrial Average was flat to close at 24,715.09, while the S&P 500 Index declined 0.26 percent to close at 2,712.97. The Nasdaq Composite Index fell 0.38 percent to close at 7,354.34.

“I don’t think this is the warning sign others seem to — I’m in the camp that the rising yield reflects an improving economy — but I am concerned about tariffs and trade policy. To me, that’s the biggest risk, and we need to see whether the negotiation process results in fairer policy,” said Lance James, who manages about $3 billion as a senior portfolio manager of U.S. equities at RBC Global Asset Management.

RDI Initiates Coverage on:

Nektar Therapeutics
https://rdinvesting.com/news/?ticker=NKTR

Corcept Therapeutics Inc.
https://rdinvesting.com/news/?ticker=CORT

Nektar Therapeutics’s stock jumped 7.66% Friday, to close the day at $85.30. The stock recorded a trading volume of 3,338,076 shares, which was above its three months average volume of 2,969,553 shares. In the last year, Nektar Therapeutics’s shares have traded in a range of 17.51 – 111.36. The share price has gained 387.15% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $88.72 is above its 200-day moving average of $75.57. Shares of Nektar Therapeutics have fallen roughly 1.06 percent in the past month and are up 42.83 percent year-to-date.

Access RDI’s Nektar Therapeutics Research Report at:
https://rdinvesting.com/news/?ticker=NKTR

On Friday, shares of Corcept Therapeutics recorded a trading volume of 1,076,348 shares, which was below the three months average volume of 1,397,698 shares. The stock ended the day 3.23% higher at $18.56. The share price has fallen 28.51% from its 52-week high with a 52-week trading range of 10.40 – 25.96. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $17.02 is below its 200-day moving average of $17.87. Shares of the company are trading at a Price to Earnings ratio of 17.85. Shares of Corcept Therapeutics have gained roughly 5.51 percent in the past month and are up 2.77 percent year-to-date.

Access RDI’s Corcept Therapeutics Incorporated Research Report at:
https://rdinvesting.com/news/?ticker=CORT

Our Actionable Research on Nektar Therapeutics (NASDAQ :NKTR) and Corcept Therapeutics Inc. (NASDAQ :CORT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 500361